Zeitschrift für diabetische Komplikationen und Medizin

Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights

Abstract

Daniel Benny

Esophageal carcinoma is a challenging malignancy with limited treatment options and poor prognosis, necessitating the exploration of novel therapeutic strategies. Metformin, a widely used drug for type 2 diabetes, has shown promising anticancer effects in various malignancies, including esophageal carcinoma. This article provides an overview of the molecular mechanisms underlying the anticancer properties of metformin in esophageal carcinoma and discusses its therapeutic potential.